Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR Eiger BioPharmaceuticals, Inc. daily Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.68 Insider Own0.20% Shs Outstand25.50M Perf Week-2.92%
Market Cap283.90M Forward P/E- EPS next Y-1.89 Insider Trans20.48% Shs Float24.90M Perf Month-19.58%
Income-66.10M PEG- EPS next Q-0.59 Inst Own73.50% Short Float4.86% Perf Quarter-12.35%
Sales- P/S- EPS this Y19.30% Inst Trans8.01% Short Ratio2.77 Perf Half Y46.43%
Book/sh2.29 P/B4.21 EPS next Y-64.30% ROA-63.40% Target Price- Perf Year-15.35%
Cash/sh3.09 P/C3.13 EPS next 5Y- ROE-115.00% 52W Range4.55 - 15.82 Perf YTD-35.23%
Dividend- P/FCF- EPS past 5Y17.00% ROI- 52W High-39.70% Beta1.48
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low109.67% ATR0.64
Employees28 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)38.14 Volatility5.63% 6.35%
OptionableYes Debt/Eq0.53 EPS Q/Q19.70% Profit Margin- Rel Volume0.33 Prev Close9.65
ShortableYes LT Debt/Eq0.47 Earnings- Payout- Avg Volume437.74K Price9.54
Recom1.00 SMA20-8.84% SMA50-10.83% SMA200-10.12% Volume12,429 Change-1.14%
Jun-26-19Initiated Citigroup Buy $22
Jan-29-19Initiated Robert W. Baird Outperform $47
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
Sep-15-20 08:54AM  
Sep-09-20 09:36AM  
Sep-01-20 08:00AM  
Aug-31-20 08:00AM  
Aug-19-20 08:49AM  
Aug-17-20 07:40AM  
Aug-06-20 04:05PM  
Aug-03-20 08:00AM  
Jul-17-20 12:16PM  
Jul-12-20 08:14PM  
Jul-08-20 12:00PM  
Jun-24-20 08:32AM  
Jun-08-20 01:22PM  
May-29-20 04:05PM  
May-26-20 04:05PM  
May-19-20 04:05PM  
May-15-20 08:57AM  
Apr-30-20 08:00AM  
Apr-22-20 10:05AM  
Apr-09-20 06:08PM  
Apr-01-20 04:05PM  
Mar-24-20 10:25AM  
Mar-23-20 08:00AM  
Mar-20-20 06:45AM  
Mar-13-20 08:00AM  
Jan-19-20 03:04PM  
Jan-15-20 05:24AM  
Jan-07-20 08:00AM  
Jan-06-20 08:00AM  
Dec-16-19 05:15PM  
Dec-07-19 01:33AM  
Nov-15-19 08:00AM  
Nov-12-19 08:45AM  
Nov-11-19 09:58AM  
Nov-07-19 04:05PM  
Oct-21-19 09:00AM  
Oct-09-19 09:47AM  
Sep-27-19 08:00AM  
Aug-29-19 04:05PM  
Aug-20-19 08:00AM  
Aug-08-19 04:05PM  
Aug-05-19 08:00AM  
Jul-31-19 08:00AM  
Jul-18-19 09:20AM  
Jul-11-19 12:42PM  
Jul-08-19 09:00AM  
Jun-20-19 07:08PM  
Jun-18-19 07:31AM  
Jun-17-19 04:16PM  
Jun-10-19 08:00AM  
Jun-05-19 08:00AM  
May-30-19 08:00AM  
May-17-19 04:05PM  
May-09-19 05:04PM  
04:01PM  
Apr-30-19 08:00AM  
Apr-26-19 02:43PM  
Apr-23-19 03:50PM  
Apr-17-19 10:53PM  
04:01PM  
Apr-15-19 08:00AM  
Apr-11-19 04:05PM  
Mar-26-19 08:00AM  
Mar-25-19 01:30PM  
Mar-20-19 08:00AM  
Mar-15-19 09:04AM  
Mar-14-19 04:19PM  
Mar-13-19 08:00AM  
Mar-11-19 08:00AM  
Mar-08-19 07:37PM  
Mar-04-19 07:00AM  
Feb-27-19 08:00AM  
Feb-06-19 08:00AM  
Feb-04-19 08:00AM  
Jan-07-19 08:00AM  
Dec-31-18 07:30AM  
Dec-21-18 09:25AM  
Dec-19-18 08:00AM  
Dec-18-18 08:00AM  
Dec-17-18 08:00AM  
Dec-11-18 02:30PM  
Dec-04-18 08:00AM  
07:59AM  
Dec-03-18 04:05PM  
08:00AM  
Nov-23-18 08:25AM  
Nov-19-18 08:00AM  
Nov-09-18 08:23AM  
08:00AM  
Oct-23-18 09:00AM  
08:35AM  
Oct-22-18 04:01PM  
08:00AM  
Oct-18-18 08:00AM  
07:56AM  
Oct-17-18 04:05PM  
08:15AM  
Oct-16-18 04:05PM  
04:05PM  
Sep-25-18 08:00AM  
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Jeffrey SDirectorAug 12Buy11.425,00057,1035,000Aug 12 06:28 PM
Glenn Jeffrey SDirectorAug 11Buy11.495,00057,46471,355Aug 12 06:28 PM
Dietz Thomas JohnDirectorMar 16Buy4.951,0004,95030,000Mar 17 05:17 PM
Glenn Jeffrey SDirectorMar 16Buy5.0330,000150,81366,355Mar 17 05:16 PM
Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerJan 24Buy13.525,00067,60330,000Jan 30 04:44 PM
Dietz Thomas JohnDirectorJan 10Buy13.944,00055,76024,000Jan 13 08:17 AM